⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791161 | 0.75 | — | — | |
| SCHEMBL4144986 | 0.75 | — | — | |
| SCHEMBL840994 | 0.73 | NQO1 (0.37) | — | |
| SCHEMBL9999337 | 0.72 | — | — | |
| SCHEMBL10197303 | 0.72 | ALOX15 (0.38) | — | |
| SCHEMBL12090870 | 0.72 | TYR (0.41) | — | |
| SCHEMBL8236942 | 0.72 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL10032704 | 0.70 | KDM4E (0.42) | — | |
| SCHEMBL4141025 | 0.70 | TYR (0.64) | — | |
| SCHEMBL14827195 | 0.70 | TYR (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118121650-A | Traditional Chinese medicine extract, preparation method thereof and blood component detection method | 川北医学院 | 2024-06-04 | — | — | CN | disclosed |
| US-11744816-B2 | Fixed dose combinations and formulations comprising ETC1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | ESPERION THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230210800-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20180133177-A1 | Treatment of NASH with Gemcabene | NEUROBO PHARMACEUTICALS, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180064671-A1 | Fixed Dose Combinations and Formulations Comprising ETC1002 and Ezetimibe and Methods of Treating or Reducing the Risk of Cardiovascular Disease | GLAS AMERICAS LLC | 2018-03-08 | — | — | US | disclosed |
| US-9855240-B2 | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2018-01-02 | — | — | US | disclosed |
| US-9849104-B2 | Treatment of NASH with gemcabene | GEMPHIRE THERAPEUTICS INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170349516-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170172955-A1 | Treatment of Mixed Dyslipidemia | NEUROBO PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170172954-A1 | Treatment of NASH with Gemcabene | NEUROBO PHARMACEUTICALS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20120129930-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8153690-B2 | Cycloalkyl-hydroxyl compounds and compositions for cholesterol management | ESPERION THERAPEUTICS, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120035141-A1 | CYCLOALKYL-HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT | ESPERION THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
| EP-2402300-A1 | Hydroxyl compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-8084498-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110003860-A1 | HYDROXYL COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2011-01-06 | — | — | US | disclosed |
| US-20090198063-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| EP-2022793-A1 | NOVEL HETEROCYCLIC COMPOUND OR SALT THEREOF AND INTERMEDIATE THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-02-11 | — | — | EP | disclosed |
| US-7335689-B2 | for example, 6,9-Dihydroxy-2,2,13,13-tetramethyl-tetradecanedioic acid, 2,2,13,13-Tetramethyl-tetradecane-1,6,9,14-tetraol, 6,10-Dihydroxy-2,2,14,14-tetramethyl-pentadecanedioic acid; treatment of Alzheimer's Disease, metabolic syndrome disorder, cancer, cardiovascular disease, diabetic nephropathy | ESPERION THERAPEUTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |